Depomed Inc

Depomed — Merger or Acquisition (September 2015)

40 slides from Depomed's merger presentation, Sep 25, 2015

  1. Slide 1: Filed pursuant to Rule 425

    Filed pursuant to Rule 425 of the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Filing by: Horizon Pharma Public Limited Company Subject Company: Depomed, Inc. SEC File No. of Depomed, Inc.: 001-13111 This Rule 425 fil

  2. Slide 2: Acquisition of Depomed, Inc. Benefits and Considerations

    Horizon Pharma plc Acquisition of Depomed, Inc. Benefits and Considerations September 2015 For Important Information About the Proposed Depomed Acquisition Please visit www.horizonanddepomed.com Non-Confidential Information – Horizon Pharma plc

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to Horizon's offer to exchange its ordinary shares for all issued and outstanding shares of Depomed’s stock and the potential strategic and financial benefits thereof,

  4. Slide 4: Note Regarding Use of Non-GAAP Financial Measures

    Note Regarding Use of Non-GAAP Financial Measures Horizon Pharma provides certain financial measures such as adjusted EBITDA, or earnings before interest, taxes, depreciation and amortization, pro forma net sales adjusted for sales of certain products pre-acquisition and adjusted net income that inc

  5. Slide 5: Horizon's Offer to Acquire Depomed Is In Our View Compelling

    Horizon’s Offer to Acquire Depomed Is In Our View Compelling For Both Depomed and Horizon Shareholders 60% Premium offer (1) Pro forma ownership above Depomed’s relevant contribution Horizon’s commercial model has potential to increase net sales Sizable expected operating cost and tax synergies Enha

  6. Slide 6: 60% Premium Offer

    60% Premium Offer(1) Horizon Pharma Has Delivered A Compelling Offer Fair and Compelling Offer Implied Premiums to Initial and Current Proposal Exchange Offer delivers a compelling premium Initial Public Revised Ratio on a number of Depomed trading Proposal Proposal Proposal (2) metrics Reference (7

  7. Slide 7: Pro Forma Ownership Above Depomed's Relevant Contribution

    Pro Forma Ownership Above Depomed’s Relevant Contribution Pro Forma Adjusted Net Income Contribution (3) Pro Forma Depomed Ownership (approximates after-tax cash flow contribution) 40% 37% 32% 30% 27% 27% 25% 20% 10% 0% (1) August 13 ProposalAugust 13 Proposal 2016E 2017E 2018E w/Debt Payoff(1) (2)

  8. Slide 8: NUCYNTA Re-Launch Results To Date Are In Our View Uninspiring

    Horizon’s Commercial Model Has Potential to Increase Net Sales NUCYNTA Re-Launch Results To Date Are In Our View Uninspiring At Week 12 Post Re-Launch, PENNSAID 2% TRx Were up 306% and VIMOVO TRx Were up 18%, While NUCYNTA IR and ER are up Only 3% and 15%, respectively % Change TRx % Change vs. Re-L

  9. Slide 9: NUCYNTA Re-Launch Results: Year-Over-Year Weekly TRx

    Horizon’s Commercial Model Has Potential to Increase Net Sales NUCYNTA Re-Launch Results To Date Are In Our View Uninspiring Year-Over-Year Weekly TRx % Increase Since NUCYNTA Re-Launch Date % Change 550% 500% 450% 400% 150% 100% 50% 0% -50% 6/12/15 6/19/15 6/26/15 7/3/15 7/10/15 7/17/15 7/24/15 7/3

  10. Slide 10: Case Study: Horizon vs. Depomed Growth Excluding NUCYNTA

    ? Horizon’s Commercial Model Has Potential to Increase Net Sales Case Study: Horizon vs. Depomed Growth Excluding NUCYNTA HZNP +42% vs DEPO -4% HZNP +35% vs DEPO +5% TRx Growth: 1H 2015 vs. 2H 2014 (1)(2) Net Sales Growth: 1H 2015 vs. 2H 2014 (1)(2) Prescriptions Net Sales 501,327 $211 352,361 $157

  11. Slide 11: Case Study: Horizon vs. Depomed Growth Including NUCYNTA

    ? Horizon’s Commercial Model Has Potential to Increase Net Sales Case Study: Horizon vs. Depomed Growth Including NUCYNTA HZNP +42% vs DEPO -4% HZNP +35% vs DEPO +13% TRx Growth: 1H 2015 vs. 2H 2014 (1)(2) Net Sales Growth: 1H 2015 vs. 2H 2014 (1)(2) Prescriptions Net Sales 656,857 630,493 $211 501,

  12. Slide 12: PENNSAID 2% Demonstrates the Power of Horizon's Model

    ? Horizon’s Commercial Model Has Potential to Increase Net Sales PENNSAID 2% Demonstrates the Power of Horizon’s Model Transaction Highlights Net Sales • Acquired in October 2014 from $35.0 Nuvo Research for $45mm $30.0 $29.4 • Immediate and rapid growth in PENNSAID 2% prescriptions $25.0 and sales

  13. Slide 13: VIMOVO Demonstrates the Power of Horizon's Model

    Horizon’s Commercial Model Has Potential to Increase Net Sales VIMOVO Demonstrates the Power of Horizon’s Model Transaction Highlights Net Sales • Acquired in November 2013 $50.0 from AstraZeneca for $35mm $45.0 $42.4 • Immediate and rapid growth in VIMOVO prescriptions and net $40.0 $34.0 sales $35

  14. Slide 14: PME has been Successful in Driving Script Growth

    Horizon’s Commercial Model Has Potential to Increase Net Sales PME has been Successful in Driving Script Growth Activating PME Throughout U.S. is Optimizing Operations and Ensuring High Level of Customer Service % of TRx Filled via PME IMS TRxs % of TRx Filled via PME IMS TRxs % of TRx Filled via PM

  15. Slide 15: Current Depomed Commercial Structure

    Horizon’s Commercial Model Has Potential to Increase Net Sales Current Depomed Commercial Structure (1) Pain / Neurology Oncology 275 Sales Reps 24 Sales Reps (1) Source: Depomed Corporate Presentation dated September 15, 2015. 14 Non-Confidential Information – Horizon Pharma plc

  16. Slide 16: Planned Structure Provides a Larger, More Focused Sales Force

    Horizon’s Commercial Model Has Potential to Increase Net Sales Planned Structure Provides a Larger, More Focused Sales Force Pain / Neurology Specialty Primary Care Orphan Diseases Rheumatology 40 Sales Reps Oncology 24 Sales Reps Neurology 14 Clinical Science 290 Sales Reps 40 Sales Reps 325 Sales

  17. Slide 17: Sizable Expected Operating Cost and Tax Synergies

    Sizable Expected Operating Cost and Tax Synergies Operational Synergies (1) Tax Synergies We believe that the costs of operating Horizon expects combined company tax rate Depomed’s existing business could be to be in the mid-single digits, increasing to significantly reduced through the elimination

  18. Slide 18: Enhanced Scale & Financial Flexibility Expected

    Enhanced Scale & Financial Flexibility Expected We believe the combined business will be larger, more diversified and better positioned to accelerate growth Horizon expects the combination would provide additional financial flexibility and increased free cash flow, enhanced access to the capital mar

  19. Slide 19: Major Diversification of Net Sales

    Major Diversification of Net Sales Reduced Reliance on NUCYNTA (1) Currently NUCYNTA accounts for 60% of Depomed’s net sales (1) Pro forma, no single medicine would comprise more than 21% of net sales Pro Forma Combined % of Net Sales DEPO % of Net Sales By Medicine (1) By Medicine (1) 4% 2% 1% 1% 3

  20. Slide 20: Horizon Patent Terms Extend Well Beyond 2025 Cliff

    Horizon’s Longer Life Products and Development Programs Horizon Patent Terms Extend Well Beyond 2025 Cliff for Depomed Products 50% of Horizon’s 2Q 2015 Net Sales Were From Medicines With Patent Terms Beyond 2025 Year 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 19 Non-Confidential Informa

  21. Slide 21: Horizon Aggressively Augments Acquired IP with Additional Filings

    Horizon’s Longer Life Products and Development Programs Horizon Aggressively Augments Acquired IP with Additional Filings… Initial IP Position IP Today • No Orange Book (OB) • 6 OB listed patents listed patents at • Settled Par litigation by granting a right to approval market beginning January 1, 2

  22. Slide 22: Strengthening IP for Orphan Medicines

    Horizon’s Longer Life Products and Development Programs …while Strengthening IP for Orphan Medicines Initial IP Position IP Today • 2 U.S. patents • 2 U.S. patents extending to 2022; perpetual extending to 2022; Genentech know-how license perpetual Genentech • Orphan Drug Designation in October 2014

  23. Slide 23: Depomed Would Benefit from Horizon's Development Programs: ACTIMMUNE

    Horizon’s Longer Life Products and Development Programs Depomed In Our View Would Benefit from Horizon’s Development Programs ACTIMMUNE in FA ACTIMMUNE Potential $500 to $1B Opportunity (1) Additional Potential Indications • Friedreich's Ataxia (FA), a debilitating, • Co-therapy with PD-1/PD-L1 inhi

  24. Slide 24: Depomed R&D Opportunity

    Horizon’s Longer Life Products and Development Programs Depomed In Our View Would Benefit from Horizon’s Development Programs DEPOMED R&D Opportunity? “We had been evaluating the performance of XARTEMIS XR. And certainly, as the • Milestone & royalty agreement related to company has changed its focu

  25. Slide 25: Substantial Reduction in Key Risks Expected

    Substantial Reduction in Key Risks Expected Depomed’s Business is Less Diversified and Highly Leveraged $ in millions Specialty Primary Care Orphan Pain Diversified Product Portfolio Patent Terms on Patent terms beyond 2025! Patent terms beyond 2025? Marketed Products Orphan Platform Potential $500M

  26. Slide 26: Published Analyst Reports Are Overwhelmingly Supportive

    Published Analyst Reports and Investors That We Have Spoken With Are Overwhelmingly Supportive “Viewing the proposed “Per our earlier note, we believe “Perception that this deal may Depomed transaction within that the asset is worth more in the not generate an adequate broader context of Horizon's h

  27. Slide 27: Total Shareholder Return as of July 6, 2015

    Published Analyst Reports and Investors That We Have Spoken With Are Overwhelmingly Supportive Total Shareholder Return as of July 6, 2015 (1) HZNP DEPO 350% 333% 300% 269% 250% 200% 168% 150% 113% 100% 45% 50% 28% 0% YTD 1 -Year 3-Year Source: Bloomberg. (1) Based on Depomed’s unaffected stock pric

  28. Slide 28: Depomed Continues to Work Against the Best Interests of Shareholders

    Depomed Continues to Work Against the Best Interests of Shareholders • Horizon attempted to engage Depomed numerous times and through intermediaries – Each attempt has been rebuffed without meaningful engagement – Depomed’s Management continues to reject a 60%+ premium(1) • Depomed has yet to explai

  29. Slide 29: Depomed Continues to Work Against the Best Interests of Shareholders

    Depomed Continues to Work Against the Best Interests of Shareholders Horizon Pharma believes that Depomed will do whatever it can to delay Depomed’s shareholders from expressing their views on Horizon Pharma’s proposals th On July 12 , Depomed’s board adopted the Poison Pill That same day, Depomed’s

  30. Slide 30: Depomed Continues to Work Against the Best Interests of Shareholders

    Depomed Continues to Work Against the Best Interests of Shareholders • Absent the Poison Pill and the most recent Depomed bylaw amendments, any Depomed shareholder(s) owning 10% or more of the shares could have called a special meeting to hear Horizon Pharma’s proposals without incurring associated

  31. Slide 31: Actions to Date in Furtherance of Our Efforts to Acquire Depomed

    Actions to Date in Furtherance of Our Efforts to Acquire Depomed On September 8 th , commenced an exchange offer to acquire all of Depomed’s common shares On September 8th, filed definitive Solicitation Materials to call for two Special Meetings of Depomed shareholders as follows(1) : Meeting One: R

  32. Slide 32: Events Expected to Occur in the Next Several Months

    Events Expected to Occur in the Next Several Months Special Meetings Oct 29 th Nov 13 th #1 Removal and Bylaw Special Meeting Request Special Meeting Request Amendments Record Date Meeting #1 Record Date Meeting #2 #2 Election of Directors Special Special TBD Meeting #1 Meeting #2 Special Meeting #1

  33. Slide 33: What We are Asking You to Do Now

    What We are Asking You to Do Now (1) Tender White and Blue Proxy Cards to call for the two Special Meetings of shareholders Meeting One: Removal of Depomed’s directors and rescission of the most recent bylaw changes (White Proxy Card) Meeting Two: Election of the new slate of directors (Blue Proxy C

  34. Slide 34: Key Transaction Events to Date

    Key Transaction Events to Date rd August 3 st Horizon publicly announces intention to seek a special August 31 SECOND OFFER (PRIVATE) shareholder meeting and files lawsuit challenging Depomed sets request for th legality of Poison Pill and the most recent changes to Meeting One record date June 25 t

  35. Slide 35: Summary of Key Exchange Offer Terms

    Summary of Key Exchange Offer Terms 0.95x exchange ratio of Horizon Pharma shares for every Depomed share Exchange ratio was set based on $33.00 per share offer price for Depomed Offer and stock and 15-day (1) volume weighted average price (VWAP) of Horizon Consideration stock as of August 12 th (2)

  36. Slide 36: Summary of Key Exchange Offer Terms

    Summary of Key Exchange Offer Terms Rescission of Poison Pill – Hearing on the legality of the Poison Pill to be held on November 5th Due diligence Horizon shareholder approval – Filed a preliminary proxy for a Special Meeting of Horizon Shareholders on Exchange September 11th Offer Competition law

  37. Slide 37: Horizon's Offer to Acquire Depomed Is In Our View Compelling

    Horizon’s Offer to Acquire Depomed Is In Our View Compelling For Both Depomed and Horizon Shareholders (1) 60% Premium offer Pro forma ownership above Depomed’s relevant contribution Horizon’s commercial model has potential to increase net sales Sizable expected operating cost and tax synergies Enha

  38. Slide 38: Additional Information

    Additional Information This communication does not constitute an offer to buy or solicitation of any offer to sell or vote securities and is for informational purposes only. It relates to the offer commenced by Horizon Pharma to exchange each issued and outstanding share of Depomed common stock for

  39. Slide 39: Certain Information Regarding Participants

    Certain Information Regarding Participants Horizon Pharma and/or Depomed and their respective directors, executive officers and certain other employees and the Horizon Pharma nominees may be deemed participants in a solicitation of proxies in connection with the requests to call the special sharehol

  40. Slide 40: Horizon Pharma plc

    Horizon Pharma plc Acquisition of Depomed, Inc. Benefits and Considerations September 2015 For Important Information About the Proposed Depomed Acquisition Please visit www.horizonanddepomed.com Non-Confidential Information – Horizon Pharma plc

Depomed — Merger or Acquisition (September 2015) on 6ix